CBL-514 is a DYRK1B inhibitor and "lipolysis drug" which is under development for the treatment of subcutaneous fat disorders such as Dercum's disease (painful lipomas), adiposis dolorosa, cellulite, and obesity.
The compounds of every Wikipedia article carrying a Chembox or a Drugbox, refreshed daily, with the values their infoboxes give. The pages need JavaScript; the API does not.